Opportunity for Improved Menopausal Hormone Therapy Prescribing

JAMA 2026

View at publisher
Authors: Deborah Bartz, A Tadikonda, James Manson
DOI: 10.1001/jama.2026.1891
Cited by: 6
References: 18

Abstract

This Perspective discusses the implications of the recent US Food and Drug Administration (FDA) label change on menopausal hormone therapy for clinicians to better integrate hormone therapy options and personalized, shared decision-making to improve care for midlife women.

Fields of Study & Subjects

Menopause: Health Impacts and Treatments Sex and Gender in Healthcare Estrogen and related hormone effects

Publication details

Journal / source
JAMA
Publisher
American Medical Association (AMA)
Volume
335
Issue
15
Pages
1297–1297
Publication date
23 March 2026
Language
EN